Apollomics Inc
apollomicsinc.comWhat Do They Do?
Develops oncology drug candidates, including targeted cancer medicines and immune-based therapies, for difficult-to-treat cancers.
20-F for FY2025, filed Apr 24, 2026
Who Are Their Customers?
Pharmaceutical partners license Apollomics' drug candidates and develop or commercialize them in their territories through licensing and collaboration agreements.
20-F for FY2025, filed Apr 24, 2026Vebreltinib (APL-101). Our most advanced product candidate is vebreltinib, a potent, oral active, highly selective c-Met inhibitor. Cancer…View ↗
APL-502. APL-502 is an anti-PD-L1 antibody product candidate and is being developed by Chia Tai Tian Qing (“CTTQ”), our partner in China.…View ↗
The Group may enter into collaboration and licensing arrangements for research and development, manufacturing, and commercialization…View ↗
In March 2025, Apollomics entered into an agreement for the development and commercialization in Asia (excluding mainland China, Hong Kong…View ↗
How Are They Changing?
Vebreltinib's development focus
The older report described vebreltinib for non-small cell lung cancer and other advanced tumors with c-Met changes; the latest names non-small cell lung cancer with c-Met amplification as its main future focus.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Apr 24, 2026APL-101. One of the most advanced drug candidates in our pipeline is our leading drug candidate, APL-101 (Vebreltinib), a potent, highly…View ↗
Vebreltinib (APL-101). Our most advanced product candidate is vebreltinib, a potent, oral active, highly selective c-Met inhibitor. Cancer…View ↗
Pipeline grouping
The older report also described drugs intended to boost chemotherapy as a separate pipeline group; the latest groups its candidates as tumor inhibitors and immune-based cancer drugs.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Apr 24, 2026Our anti-cancer enhancer drug candidates consist of two antagonists against a cell adhesion receptor (E-selectin), APL-106 and APL-108…View ↗
The product candidates in our pipeline can be categorized into two groups based on their mechanisms of action, each of which contains…View ↗
Loading...
